Differential use of extended and immediate release quetiapine: A retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders

BMJ Open

Volumn 2, Issue 4, 2012, Pages

  Hallinen, Taru ^a   Soini, Erkki J ^a   Granström, Ola ^b   Ovaskainen, Yrjö ^c   Leinonen, Esa ^d   Koponen, Hannu J ^e   Hänninen, Kari ^f  

^a Esior Oy   (Finland)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA   (United Kingdom)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f SOUTH KARELIA CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; NEUROLEPTIC AGENT; QUETIAPINE;

ADOLESCENT; ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE REGISTRY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; FEMALE; FINLAND; HEALTH CARE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; MONOTHERAPY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84864085885     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-000915     Document Type: Article

References (30)

1. Van Snellenberg JX, de Candia T. Meta-analytic evidence for familial coaggregation of schizophrenia and bipolar disorder. Arch Gen Psychiatry 2009;66:748-55.
2. Carroll LS, Owen MJ. Genetic overlap between autism, schizophrenia and bipolar disorder. Genome Med 2009;1:102.
3. Laursen TM, Agerbo E, Pedersen CB. Bipolar disorder, schizoaffective disorder, and schizophrenia overlap: a new comorbidity index. J Clin Psychiatry 2009;70:1432-8.
4. Buchanan RW, Kreyenbuhl J, Kelly DL, et al Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;1:71-93.
5. National Institute for Clinical Excellence (NICE). Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance No. 43. London, 2002.
6. Malhi GS, Adams D, Lampe L, et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl 2009;439:27-46.
7. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and anxiety treatments (CANMAT) and international Society for bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009;11:225-55.
8. Altamura AC, Armadoros D, Jaeger M, et al. Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective. Curr Med Res Opin 2008;24:2271-82.
9. Parks J, Radke A, Parker G, et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull 2009;35:931-6.
10. Jindal RD, Keshavan MS. Classifying antipsychotic agents: need for new terminology. CNS Drugs 2008;22:1047-59.
11. Peuskens J, Trivedi J, Malyarov S, et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry (Edgmont) 2007;4:34-50.
12. Datto C, Berggren L, Patel JB, et al. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extendedrelease quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 2009;31:492-502.
13. Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:199-204.
14. Meulien D, Huizar K, Brecher M. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies. Hum Psychopharmacol 2010;25:103-15.
15. Soini EJ, Rissanen T, Tiihonen J, et al. Predicting forensic admission among the mentally ill in a multinational setting: a Bayesian modelling approach. Data Knowledge Eng 2009;68:1427-40.
16. Karagianis J, Williams R, Davis L, et al. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia. Curr Med Res Opin 2009;25:2121-32.
17. Procyshyn RM, Honer WG, Wu TK, et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 2010;71:566-73.
18. Ranceva N, Ashraf W, Odelola D. Antipsychotic polypharmacy in outpatients at Birch Hill Hospital: incidence and adherence to guidelines. J Clin Pharmacol 2010;50:699-704.
19. Kroken RA, Johnsen E, Ruud T, et al. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry 2009;9:24.
20. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549-57. (Pubitemid 27258553)
21. Gardner DM, Murphy AL, O'Donnell H, et al. International consensus study of antipsychotic dosing. Am J Psychiatry 2010;167:686-93.
22. Kane JM, Leucht S, Carpenter D, et al. Expert consensus guideline series. Optimizing pharmacological treatment of psychotic disorders: medication selection, dosing and dose equivalence. J Clin Psychiatry 2003;64(Suppl 12):21-51.
23. Nyberg S. Predictive modeling - impact of varying doses and different formulations on receptor occupancy profile for quetiapine [abstract]. 23rd ECNP Congress 28 August 2010-01 September 2010. Eur Neuropsychopharmacol 2010;20(Suppl 3):P264.
24. Stahl SM. Essential Psychopharmacology: the Prescriber's Guide. New York: Cambridge University Press, 2006:427-32.
25. Bitter I, Chou JC, Ungvari GS, et al. Prescribing for inpatients with schizophrenia: an international multi-center comparative study. Pharmacopsychiatry 2003;36:143-9. (Pubitemid 37041334)
26. Eriksson L, Hallerbäck T, Jorgensen L, et al. Use of Quetiapine XR and Quetiapine IR In Clinical Practice for Hospitalized Schizophrenic Patients - A Retrospective Study. Abstract and poster, 2nd International Congress on Neurobiology, Psychopharmacology and Treatment Guidance, Thessaloniki, Greece, 24-27 November 2011, International Society of Neurobiology and Psychopharmacology, 2011.
27. Remington G, Kwon J, Collins A, et al. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res 2007;90:229-37. (Pubitemid 46177579)
28. Diaz E, Neuse E, Sullivan MC, et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004;65:354-60.
29. 2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. Int J Neuropsychopharmacol 2011;14:1357-66.
30. Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate release formulation: a positron emission tomography study. J Clin Psychiatry 2008;69:81-6. (Pubitemid 351282000)